Therapeutic strategies in RET gene rearranged non-small cell lung cancer

The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches. RET gene fusions are oncogenic drivers in multiple tumor types and are known to occur...

Descripción completa

Detalles Bibliográficos
Autores principales: Drusbosky, Leylah M., Rodriguez, Estelamari, Dawar, Richa, Ikpeazu, Chukwuemeka V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995721/
https://www.ncbi.nlm.nih.gov/pubmed/33771190
http://dx.doi.org/10.1186/s13045-021-01063-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995721/
https://www.ncbi.nlm.nih.gov/pubmed/33771190
http://dx.doi.org/10.1186/s13045-021-01063-9

Ejemplares similares